Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Director Craig A. Collard Acquires 2,500 Shares

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Director Craig A. Collard acquired 2,500 shares of Opiant Pharmaceuticals stock in a transaction on Monday, September 13th. The shares were bought at an average price of $18.13 per share, with a total value of $45,325.00. Following the purchase, the director now directly owns 16,077 shares in the company, valued at approximately $291,476.01. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Shares of Opiant Pharmaceuticals stock opened at $23.34 on Friday. The company has a quick ratio of 10.46, a current ratio of 10.46 and a debt-to-equity ratio of 0.52. Opiant Pharmaceuticals, Inc. has a twelve month low of $6.79 and a twelve month high of $23.65. The business has a 50-day moving average price of $16.85 and a 200 day moving average price of $13.90. The firm has a market cap of $102.70 million, a PE ratio of -64.83 and a beta of 0.75.

Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its quarterly earnings results on Thursday, August 5th. The technology company reported $0.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.59. Opiant Pharmaceuticals had a negative return on equity of 3.17% and a negative net margin of 3.06%. The firm had revenue of $11.26 million during the quarter, compared to analyst estimates of $8.01 million. On average, sell-side analysts expect that Opiant Pharmaceuticals, Inc. will post -0.95 EPS for the current year.

A number of equities analysts have weighed in on the company. Northland Securities assumed coverage on Opiant Pharmaceuticals in a research note on Wednesday, July 7th. They set a “buy” rating and a $42.00 price objective for the company. TheStreet upgraded Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research note on Wednesday, July 7th.

Hedge funds have recently bought and sold shares of the stock. Morgan Stanley boosted its holdings in Opiant Pharmaceuticals by 11.8% in the 1st quarter. Morgan Stanley now owns 9,476 shares of the technology company’s stock worth $101,000 after buying an additional 1,000 shares during the last quarter. Geode Capital Management LLC acquired a new stake in Opiant Pharmaceuticals in the 1st quarter worth about $136,000. Dimensional Fund Advisors LP boosted its holdings in Opiant Pharmaceuticals by 11.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 21,831 shares of the technology company’s stock worth $232,000 after buying an additional 2,253 shares during the last quarter. Northern Trust Corp boosted its holdings in Opiant Pharmaceuticals by 17.6% in the 2nd quarter. Northern Trust Corp now owns 37,958 shares of the technology company’s stock worth $507,000 after buying an additional 5,668 shares during the last quarter. Finally, Apis Capital Advisors LLC boosted its holdings in shares of Opiant Pharmaceuticals by 5.0% during the 2nd quarter. Apis Capital Advisors LLC now owns 84,000 shares of the technology company’s stock worth $1,123,000 after purchasing an additional 4,000 shares during the last quarter. Institutional investors own 19.92% of the company’s stock.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.

Featured Story: Do You Need a Fiduciary?

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.